Research programme: therapeutics - Jazz Pharmaceuticals
Latest Information Update: 26 Feb 2024
At a glance
- Originator Jazz Pharmaceuticals plc
- Class Antiepileptic drugs; Neuroprotectants; Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Epilepsy; Neurological disorders; Sleep disorders
Most Recent Events
- 26 Feb 2024 Preclinical trials in Epilepsy in Ireland (unspecified route) (Jazz Pharmaceuticals plc Pipeline, February 2024)
- 26 Feb 2024 Preclinical trials in Sleep disorders in Ireland (unspecified route) (Jazz Pharmaceuticals plc Pipeline, February 2024)
- 01 Jan 2021 Preclinical trials in Neurological disorders in Ireland before January 2021 (Jazz Pharmaceuticals pipeline, January 2021)